利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.018 秒)

    Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
    1.
    发明授权
    Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics 有权
    金丝桃素和金丝桃提取物：特异性T型钙通道阻断剂，其作为T型钙通道靶向治疗剂

    公开(公告)号：US07195783B2

    公开(公告)日：2007-03-27

    申请号：US09481572

    申请日：2000-01-11

    申请人： Jacqueline J. Shan ,  Xi-Chen Wu ,  Peter K. T. Pang ,  Lei Ling

    发明人： Jacqueline J. Shan ,  Xi-Chen Wu ,  Peter K. T. Pang ,  Lei Ling

    IPC分类号： A01N65/00

    CPC分类号： A61K31/235 ,  A61K31/12 ,  A61K31/185 ,  A61K31/192 ,  A61K36/38

    摘要： Hypericin has been shown to specifically inhibited T-type calcium channel activity. Hypericum extract containing hypericin also inhibited T-type calcium channel activity. Moreover, other chemicals in Hypericum extract showed a synergistic effect to hypericin. In view of this, hypericin or hypericin-containing Hypericum extract can be used as T-channel blockers. Hypericum extract, extract of other species of the Hypericum genus, extract of other plants containing hypericin, hypericin, hypericin derivatives, hypericin analogs, such as pseudohypericin, and other hypericum extract constituents can be used as therapeutics targeted at T-type calcium channels for treatment of diseases associated with T-channel abnormality. Methods for administering hypericin and hypericum extract are disclosed.

    摘要翻译： 已显示金丝桃素特异性抑制T型钙通道活性。 含金丝桃素的金丝桃提取物也抑制T型钙通道活性。 此外，金丝桃提取物中的其他化学物质显示出对金丝桃素的协同作用。 鉴于此，金丝桃素或含金丝桃酸的金丝桃提取物可用作T通道阻断剂。 金丝桃提取物，金丝桃属的其他物种的提取物，含有金丝桃素的金丝桃素，金丝桃素，金丝桃素衍生物，金丝桃素类似物例如假倍他辛和其他金丝桃提取物成分的提取物可用作靶向T型钙通道的治疗剂用于治疗 的与T通道异常相关的疾病。 公开了金丝桃素和金丝桃提取物的施用方法。

    Chemical and pharmacological standardization of herbal extracts
    2.
    发明授权
    Chemical and pharmacological standardization of herbal extracts 有权
    草药提取物的化学和药理标准化

    公开(公告)号：US6156291A

    公开(公告)日：2000-12-05

    申请号：US143361

    申请日：1998-08-28

    申请人： Peter K. T. Pang ,  Jacqueline J. Shan ,  Kam Wai Chiu

    发明人： Peter K. T. Pang ,  Jacqueline J. Shan ,  Kam Wai Chiu

    IPC分类号： A61K36/00 ,  A61P25/28 ,  G01N33/50 ,  G01N33/94 ,  A01N65/00 ,  A61K35/78 ,  A61K49/00

    CPC分类号： G01N33/94 ,  A61K36/00 ,  G01N33/5088 ,  G01N2800/52

    摘要： One of the aspects of the present invention relates to a method of obtaining a reproducible extraction process for use as a standard process for extracting a pharmacologically active mixture of chemical components from a plant, the method comprising: (a) extracting a plurality of pharmacologically active mixtures of chemical components from the plant in a plurality of different extraction processes to obtain a plurality of extracts;(b) obtaining a biological fingerprint of the pharmacological activity of each extract from step (a) by conducting at least two in vitro and at least two in vivo pharmacological tests on each extract, wherein each of the tests is known to correlate with effective treatment of a medical condition in a patient;(c) choosing one of the plurality of extracts which displays the best pharmacological activity in step (b);(d) repeating, at least once, the extraction process used to produce the chosen extract of step (c) to produce at least one test extract;(e) (1) obtaining chemical fingerprints of the chosen extract and the at least one test extract by distinguishing the identity and amount, relative to each other, of the chemical components in the pharmacologically active mixture of each extract, and(2) repeating said step (b) using the at least one test extract; and(f) comparing the chemical fingerprints and the biological fingerprints of the chosen extract and the at least one test extract.

    摘要翻译： 本发明的一个方面涉及一种获得可再现提取方法的方法，该方法用作从植物中提取化学成分的药理学活性混合物的标准方法，所述方法包括：（a）提取多种药理活性 在多个不同提取方法中来自植物的化学成分的混合物以获得多种提取物; （b）通过对每种提取物进行至少两次体外和至少两次体内药理学试验来获得步骤（a）的每种提取物的药理活性的生物学指纹，其中每个测试已知与有效治疗相关 患者的医疗状况; （c）选择在步骤（b）中显示最佳药理活性的多种提取物之一; （d）至少一次重复用于产生所选择的步骤（c）的提取物的提取方法以产生至少一种测试提取物; （e）（1）通过区分每种提取物的药理活性混合物中的化学成分相对于彼此的身份和数量来获得所选提取物和至少一种测试提取物的化学指纹，和（2）重复 所述步骤（b）使用所述至少一种测试提取物; 和（f）比较所选择的提取物和至少一种测试提取物的化学指纹图谱和生物指纹图谱。

    Active component of parathyroid hypertensive factor
    5.
    发明授权
    Active component of parathyroid hypertensive factor 失效
    甲状旁腺高血压因子的活性成分

    公开(公告)号：US5739274A

    公开(公告)日：1998-04-14

    申请号：US387820

    申请日：1995-02-24

    申请人： Peter K. T. Pang ,  Christina G. Benishin ,  Shan Jie ,  Richard Z. Lewanczuk

    发明人： Peter K. T. Pang ,  Christina G. Benishin ,  Shan Jie ,  Richard Z. Lewanczuk

    IPC分类号： G01N33/50 ,  A61K38/00 ,  A61K39/395 ,  A61P9/12 ,  C07K1/113 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  G01N33/577 ,  G01N33/68 ,  G01N33/78 ,  G01N33/92 ,  C07K7/04

    CPC分类号： C07K16/18 ,  C07K14/47 ,  G01N33/6872 ,  G01N33/92 ,  A61K38/00

    摘要： An active component of parathyroid hypertensive factor (PHF) which comprises a polypeptide linked to a phospholipid has been identified. The component has activities substantially similar to parathyroid hypertensive factor and therefore is indicated in the control of extracellular calcium uptake, and is related to hypertension and some other diseases in mammals. Method for screening patients for the presence of the circulating factor using antibodies against the component are described. Antagonists of the parathyroid hypertensive factor component have been developed and their use in methods of treating patients with diseases which involve intracellular calcium elevation are also described.

    摘要翻译： PCT No.PCT / US93 / 05626 Sec。 371日期：1995年2月24日 102（e）1995年2月24日PCT PCT 1993年6月14日PCT公布。 出版物WO93 / 25577 日期：1993年12月23日已经鉴定了包含与磷脂连接的多肽的甲状旁腺高血压因子（PHF）的活性成分。 该组分具有与甲状旁腺高血压因子基本相似的活性，因此在细胞外钙摄取的控制中被指出，并且与哺乳动物中的高血压和一些其它疾病有关。 描述了使用针对组分的抗体筛选患者循环因子的存在的方法。 已经开发了甲状旁腺高血压因子成分的拮抗剂，并且还描述了它们在治疗涉及细胞内钙升高的疾病患者的方法中的用途。

    Parathyroid hypertensive factor, antibodies and uses thereof
    7.
    发明授权
    Parathyroid hypertensive factor, antibodies and uses thereof 失效
    甲状旁腺高血压因子，抗体及其用途

    公开(公告)号：US5192664A

    公开(公告)日：1993-03-09

    申请号：US603745

    申请日：1990-11-21

    申请人： Peter K. T. Pang ,  Richard Z. Lewanczuk ,  Christine G. Benishin ,  Toyoii Kaneko

    发明人： Peter K. T. Pang ,  Richard Z. Lewanczuk ,  Christine G. Benishin ,  Toyoii Kaneko

    IPC分类号： A61K31/275 ,  A61K31/44 ,  A61K31/55 ,  C07K14/47 ,  C07K16/18

    CPC分类号： C07K16/18 ,  A61K31/275 ,  A61K31/44 ,  A61K31/55 ,  C07K14/4702 ,  Y10S530/80 ,  Y10S530/806

    摘要： A new circulating factor from the parathyroid gland of some hypertensive mammals have been isolated and characterized. Polyclonal and monoclonal antibodies raised against this factor are usable as a screen for the presence of the factor. The factor is involved in the control of calcium uptake in cells. Hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly. The factor has a molecular weight of 3,000 to 4,000 Daltons.

    摘要翻译： PCT No.PCT / US90 / 01577 Sec。 371日期1990年11月21日 102（e）1990年11月21日日期PCT 1990年11月21日PCT PCT。 出版物WO90 / 11074 1990年10月4日。一些高血压哺乳动物甲状旁腺的新循环因子被分离和表征。 针对该因素产生的多克隆和单克隆抗体可用作该因子存在的筛选。 该因素涉及细胞中钙吸收的控制。 可以通过施用钙通道阻断剂和钙补充剂和维生素D中的一种或两种来治疗高血压哺乳动物以降低平均血压。该组合的降血压作用是协同的，并且剂量反应比任何 的这些药剂。 该因子的分子量为3,000至4,000道尔顿。

    Processes of making North American ginseng fractions, products containing them, and use as immunomodulators
    10.
    发明授权
    Processes of making North American ginseng fractions, products containing them, and use as immunomodulators 有权
    制作北美西参人造片，含有它们的产品，用作免疫调节剂的方法

    公开(公告)号：US07067160B2

    公开(公告)日：2006-06-27

    申请号：US10187289

    申请日：2002-07-02

    申请人： Jacqueline J. Shan ,  Peter K. T. Pang ,  Buhan Huang ,  Lei Ling

    发明人： Jacqueline J. Shan ,  Peter K. T. Pang ,  Buhan Huang ,  Lei Ling

    IPC分类号： A61K35/78

    CPC分类号： A61K39/39 ,  A61K36/258 ,  A61K2039/55583 ,  A61K2039/55588 ,  Y10S514/885

    摘要： This invention is directed towards processes of making fractions from North American ginseng and to compositions containing these fractions. This invention is also directed towards methods of methods of preparing pharmaceuticals containing these fractions. Additionally, this invention is directed towards methods of stimulating the production of immunoglobins by administering fractions of this invention and also to methods of activating B-lymphocyte proliferation and antibody production by administering fractions of this invention. This invention is also directed towards a method of stimulating the production of IL-16, IL-1, and/or TNF-α in cells by administering a fraction of this invention.

    摘要翻译： 本发明涉及从北美人参制成级分的方法以及含有这些级分的组合物。 本发明还涉及制备含有这些级分的药物的方法的方法。 此外，本发明涉及通过施用本发明的级分刺激免疫球蛋白的产生的方法，还涉及通过施用本发明的级分来激活B淋巴细胞增殖和抗体产生的方法。 本发明还涉及通过施用本发明的一部分来刺激细胞中IL-16，IL-1和/或TNF-α的产生的方法。